Barclays raised the firm’s price target on Argenx to EUR 390 from EUR 375 and keeps an Equal Weight rating on the shares. The firm update its model to reflect the approval of Vyvgart in chronic inflammatory demyelinating polyneuropathy in the U.S., saying the label is in-line with expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- argenx Unveils Innovative CIDP Treatment VYVGART Hytrulo
- argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
- Argenx announces FDA approval of VYVGART Hytrulo
- Argenx Unveils ‘Vision 2030’ for Transforming Autoimmunity
- argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024